newsfilter
← Latest News
Business Wire·

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

  • TriSalus Life Sciences (NASDAQ: TLSI) announced participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting in Toronto, Ontario, Canada, from April 11–15, 2026.
  • The company will showcase clinical & preclinical data demonstrating its Pressure Enabled Drug Delivery™ (PEDD™) platform capabilities across multiple disease states.
  • Featured presentations include a poster on hepatic tumor penetration in an oncopig model presented by David Jaroch on April 13.
  • A scientific session on liver metastases embolization before & after PEDD introduction will be presented by Adam Robinson & Richard Marshall on April 13.
  • A scientific session assessing safety & efficacy of uterine artery embolization using PEDD will be presented by Francis Kang on April 14.
  • CEO Mary Szela stated the presentations expand evidence supporting PEDD as a differentiated approach with versatile applications from liver therapies to uterine artery embolization.
  • CMO Richard Marshall highlighted the company's commitment to advancing interventional oncology & embolization techniques through data ranging from pre-clinical to human studies.
  • TriSalus utilizes three FDA-cleared PEDD devices: the TriNav® Infusion System, TriNav Infusion System LV, & the Pancreatic Retrograde Venous Infusion System.
  • The company's investigational immunotherapeutic nelitolimod, a class C Toll-like receptor 9 agonist, targets the immunosuppressive tumor environment in liver & pancreas applications.
  • Patient data from Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials suggests nelitolimod delivered via PEDD may have favorable immune effects.
  • TriSalus is completing phase 1 clinical trial data & plans to explore partnership opportunities for development.
  • Forward-looking statements in the release include financial outlooks for 2025 & 2026, clinical development timelines, & regulatory approval risks.